{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:22:35Z","timestamp":1790670155649,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["SU2C-AACR-PCC-01\\u201318"],"award-info":[{"award-number":["SU2C-AACR-PCC-01\\u201318"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116782","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:24:58Z","timestamp":1778084698000},"page":"116782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer"],"prefix":"10.1016","volume":"241","author":[{"given":"Ashwini C.","family":"Kanhailal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Knikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybrand W.J.","family":"Zielhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila L.","family":"Kodach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Bernards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent M.","family":"Gerrits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinke","family":"Huisman-Siebinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mainardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans L.","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2026.116782_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"43","key":"10.1016\/j.ejca.2026.116782_bib2","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2026.116782_bib3","series-title":"Update: mutations in human cancers through the lens of KRAS","author":"JHaM","year":"2021"},{"issue":"1","key":"10.1016\/j.ejca.2026.116782_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.ejca.2026.116782_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2026.116782_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2026.116782_bib7","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"Jama"},{"issue":"34","key":"10.1016\/j.ejca.2026.116782_bib8","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116782_bib9","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116782_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","article-title":"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3","volume":"7","author":"Sun","year":"2014","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.ejca.2026.116782_bib11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116782_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.116782_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/s41416-020-0776-z","article-title":"Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1\/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer","volume":"122","author":"van Geel","year":"2020","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.116782_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00280-020-04066-4","article-title":"Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer","volume":"85","author":"Huijberts","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116782_bib15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/onco.13631","article-title":"Phase I study of afatinib and selumetinib in patients with KRAS-mutated colorectal, non-small cell lung, and pancreatic cancer","volume":"26","author":"van Brummelen","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ejca.2026.116782_bib16","article-title":"Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer","volume":"3","author":"Frank","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2026.116782_bib17","article-title":"Investigator\u2019s brochure SAR442720\/RMC-4630","author":"Sanofi-Aventis Recherche & D\u00e9veloppement","year":"2022","journal-title":"Sanofi"},{"key":"10.1016\/j.ejca.2026.116782_bib18","series-title":"LY3214996 investigator\u2019s brochureeli","author":"Laboratories","year":"2020"},{"issue":"2","key":"10.1016\/j.ejca.2026.116782_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/PAS.0000000000000989","article-title":"CDKN2A\/B deletion and double-hit mutations of the MAPK pathway underlie the aggressive behavior of langerhans cell tumors","volume":"42","author":"Xerri","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116782_bib20","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1073\/pnas.1011989109","article-title":"Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma","volume":"109","author":"Lin","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8_ement_2","key":"10.1016\/j.ejca.2026.116782_bib21","article-title":"Abstract CT073: a first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors","volume":"85","author":"Lin","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116782_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-026-01340-1","article-title":"A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors","author":"Falchook","year":"2026","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116782_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/JIPO.JIPO_17_18","article-title":"Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials","volume":"2","author":"Chin","year":"2020","journal-title":"J Immunother Precis Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116782_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated With BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ejca.2026.116782_bib25","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3390\/ijms26062667","article-title":"The role of the MAPK signaling pathway in cardiovascular disease: pathophysiological mechanisms and clinical therapy","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.ejca.2026.116782_bib26","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/CIRCULATIONAHA.107.728865","article-title":"Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase\/mitogen-activated protein kinase and RhoA signaling pathways","volume":"117","author":"Kontaridis","year":"2008","journal-title":"Circulation"},{"issue":"13_ement","key":"10.1016\/j.ejca.2026.116782_bib27","article-title":"Abstract LB001: anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers","volume":"81","author":"Koczywas","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116782_bib28","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0959-8049(20)31089-3","article-title":"Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b\/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling","volume":"138","author":"Bendell","year":"2020","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2026.116782_bib29","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jtho.2022.07.022","article-title":"OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors","volume":"17","author":"Falchook","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"9,ement","key":"10.1016\/j.ejca.2026.116782_bib30","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/j.jtho.2022.07.794","article-title":"EP08.02-111 RMC-4630, a SHP2 inhibitor, in combination with sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: a phase 2 trial","volume":"17","author":"Johnson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116782_bib31","doi-asserted-by":"crossref","unstructured":"Pant S., Bendell J.C., Sullivan R.J., Shapiro G., Millward M., Mi G., et al. A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). Journal of Clinical Oncology.37(15_suppl):3001-.","DOI":"10.1200\/JCO.2019.37.15_suppl.3001"},{"key":"10.1016\/j.ejca.2026.116782_bib32","author":"Brian","year":"2025","journal-title":"J Clin Oncol ASCO Publ"},{"key":"10.1016\/j.ejca.2026.116782_bib33","article-title":"A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors","author":"Xinghao","year":"2025","journal-title":"J Clin Oncol ASCO Publ"},{"issue":"1","key":"10.1016\/j.ejca.2026.116782_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O'Quigley","year":"1990","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.ejca.2026.116782_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104112","article-title":"The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the drug rediscovery protocol (DRUP)","volume":"10","author":"Verkerk","year":"2025","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ejca.2026.116782_bib36","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cimb46040177","article-title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer","volume":"46","author":"Stefanoudakis","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116782_bib37","article-title":"Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer","volume":"41","author":"Abraham","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:04:01Z","timestamp":1783105441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S0959804926005630"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116782","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116782"}}